A Phase 1, Dose-finding and Signal-seeking Study of the Safety and Efficacy of Intravenous CAVATAK® (Coxsackievirus A21, CVA21) Alone and in Combination With Pembrolizumab in Patients With Late Stage Solid Tumours (NSCLC, Castrate-resistant Prostate Cancer, Melanoma, Bladder Cancer).

Trial Profile

A Phase 1, Dose-finding and Signal-seeking Study of the Safety and Efficacy of Intravenous CAVATAK® (Coxsackievirus A21, CVA21) Alone and in Combination With Pembrolizumab in Patients With Late Stage Solid Tumours (NSCLC, Castrate-resistant Prostate Cancer, Melanoma, Bladder Cancer).

Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs CVA 21 (Primary) ; Pembrolizumab
  • Indications Bladder cancer; Malignant melanoma; Non-small cell lung cancer; Prostate cancer; Solid tumours
  • Focus Therapeutic Use
  • Acronyms KEYNOTE-200; STORM
  • Sponsors Viralytics
  • Most Recent Events

    • 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 05 Apr 2017 According to a Viralytics media release, company has completed enrollment of ten patients in the combination dose escalation phase of the study and recruitment of the expansion cohort of 80 patients is ongoing. Company intends to open sites in Australia and the UK.
    • 05 Apr 2017 According to a Viralytics media release, data from this study has been presented at the American Association for Cancer Research Annual Meeting 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top